Professor Greg Dore and Dr Joanne Bryant – Hepatitis C Elimination in Australia: are we on-track?

Event type: 
Seminar
Event date: 
Tuesday, 24 July 2018 - 12:30pm to 2:00pm
Location: 
Berg Family Foundation Seminar Room, Level 6, Wallace Wurth Building, Kensington Campus, UNSW Sydney
Contact for bookings: 
Rata Joseph, +61 (2) 9385 0900 or recpt@kirby.unsw.edu.au
Booking deadline: 
Monday, 23 July 2018 - 10:00am

A catered lunch will be provided at 12:30pm. Please RSVP to recpt@kirby.unsw.edu.au by 10am Monday 23 July.

Kirby Institute Seminar Series presents a World Hepatitis Day Special Seminar

Professor Gregory Dore

Professor Gregory Dore

Head, Viral Hepatitis Clinical Research Program, Kirby Institute

Professor Gregory Dore is Head, Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Sydney, and Infectious Diseases Physician, St Vincent’s Hospital, Sydney, Australia. He has been involved in viral hepatitis and HIV epidemiological and clinical research, clinical care and public health policy for 20 years.

Twitter: @GregDore2

Dr Joanne Bryant

Dr Joanne Bryant

Senior Research Fellow, Centre for Social Research in Health, UNSW

Dr Joanne Bryant is a Senior Research Fellow at the Centre for Social Research in Health in the Faculty of Arts and Social Sciences. She holds a PhD in sociology and an MSc in epidemiology. She has led a range of impactful research projects focusing on young people’s alcohol and drug use and sexual health, concentrating specifically on populations of vulnerable young people including street-involved youth and Indigenous youth. She holds an affiliated appointment with the UNSW Practical Justice Initiative, a program of interdisciplinary research focusing on innovative solutions to social problems.

Abstract

Australia has established the foundation to achieve elimination of HCV as a major public health issue, including WHO goals of 80% treated, 90% reduction in HCV incidence, and 65% reduction in liver disease mortality. Since March 2016, more than 60,000 people have commenced HCV therapy, however, treatment numbers are declining. Key issues are treatment levels required to achieve HCV elimination goals, and strategies to enhance access to priority populations.

#WHD2018 #NOhep #EliminateHepatitis

Location

Events